Thalassemia is a collective term for a group of blood disorders characterized by reduced or absent production of one or more of the normal globin chains that make up hemoglobin. These disorders can be classified as α, β, γ, δ, δβ, or εγδβ thalassemias, depending on which specific chain synthesis is impaired. Among the various types, α and β thalassemias are the most clinically significant, as they involve a decrease in either the α or β polypeptide chains that form the normal adult hemoglobin molecule (Hb A, α2β2). Inheritance of thalassemias is typically recessive in nature.
Beta thalassemia is a hereditary blood disorder characterized by reduced or absent production of hemoglobin, leading to severe anemia. β-thalassemia is further classified based on the reduction (β+) or absence (β0) of globin chain production, which can result in anemia and various forms of syndromic manifestations.
Types of beta thalassemia
The different types of beta thalassemia are:
• Beta thalassemia major, also known as Cooley's anemia, represents the most severe form of beta-thalassemia. It is characterized by the absence or dysfunction of two beta-globin genes. This condition is now referred to as "transfusion-dependent thalassemia," as individuals with this type necessitate lifelong blood transfusions.
• Beta thalassemia intermedia can lead to mild to moderate symptoms of anemia. Similar to beta thalassemia major, it involves the absence or dysfunction of two beta-globin genes. However, individuals with beta-thalassemia intermedia typically do not require lifelong blood transfusions.
• Beta thalassemia minor, also referred to as beta thalassemia trait, often manifests with mild symptoms of anemia. This type is characterized by the absence or dysfunction of one beta-globin gene. Some individuals with beta thalassemia minor may not experience any symptoms at all.
Transfusion-dependent variant (TDT) of beta Thalassemia is a challenging clinical condition that needs life-long treatment and monitoring, ideally in specialized centers and by multidisciplinary expert teams.
Treatment Modalities for Beta Thalassemia
The treatment approach for beta thalassemia aims to manage symptoms, improve quality of life, and prevent complications associated with the condition. Treatment strategies for beta thalassemia may include blood transfusions, Iron Chelation Therapy, Folic Acid Supplementation, Bone Marrow Transplantation, and Gene Therapy.
• Blood Transfusions
Blood transfusions are the cornerstone of treatment for individuals with beta-thalassemia major, the most severe form of the condition. Transfusion therapy for individuals with β-thalassemia major aims to sustain adequate hemoglobin levels in the bloodstream and address the anemia caused by insufficient endogenous erythropoiesis. The goal of transfusion rehabilitation is to maintain the appropriate hemoglobin levels and alleviate the symptoms associated with anemia.
The frequency of blood transfusions depends on the individual's clinical condition and is often determined by measuring the patient's hemoglobin levels. Most patients receive transfusions every two to four weeks, but some may require more frequent transfusions to maintain adequate hemoglobin levels. Regular monitoring of iron overload is essential because repeated transfusions can lead to excessive iron accumulation in the body.
• Chelation Therapy
Iron overload resulting from frequent blood transfusions is a significant concern for individuals with beta-thalassemia. Each red blood cell (RBC) contains approximately 200 mg of iron during regular blood transfusions. Consequently, this leads to an accumulation of iron in the body at a rate of approximately 0.3-0.6 mg/kg per day. To prevent the toxic effects of excess iron, chelation therapy is employed. Chelating agents such as deferoxamine, deferiprone, and deferasirox help remove excess iron from the body through urine or feces.
Long-term adherence to chelation therapy is crucial to prevent complications associated with iron overload, such as cardiac dysfunction, liver disease, and endocrine abnormalities. Regular monitoring of iron levels, cardiac function, and potential adverse effects of chelating agents is necessary to ensure optimal treatment outcomes.
• Gene Therapy
Gene therapy holds promising potential as a curative approach for beta-thalassemia. It involves introducing a functional copy of the mutated gene responsible for beta-thalassemia into the patient's cells to restore normal hemoglobin production. This therapy aims to reduce or eliminate the need for lifelong transfusions and associated complications.
In gene therapy, patients' stem cells are used to treat beta-thalassemia permanently. First, patients' hematopoietic stem and progenitor cells (HSPCs) are extracted from their umbilical cord blood, peripheral blood, or bone marrow. These cells are used to compensate for the mutation in faulty genes. This can be achieved by
• Gene addition is accomplished through the semi-random insertion of a healthy copy of the therapeutic gene into cells using viral vectors. The viral vectors include lentiviruses or adeno-associated viruses.
• Gene editing is accomplished through a precisely directed mutation that repairs the gene in situ or induces a disease-modifying effect (i.e., reactivation of Hb F synthesis) using site-specific nucleases.
Although gene therapy for beta-thalassemia is still in the experimental stage, promising results have been reported in clinical trials. Some patients have achieved sustained production of functional hemoglobin, allowing them to reduce or discontinue transfusions.
The management of beta-thalassemia relies on a multi-pronged approach that addresses symptoms and complications associated with the disorder. Treatment decisions should be individualized, considering the severity of the condition, the patient's age, overall health, and available resources. Regular monitoring, including blood tests and specialized imaging studies, is crucial to assess treatment efficacy, identify potential complications, and make necessary adjustments to the treatment plan.
However, regardless of the type of beta thalassemia, it is crucial to collaborate with healthcare professionals with expertise in diagnosing and managing thalassemia. By seeking the guidance of experienced specialists, you can ensure the most appropriate and effective treatment for your specific case of thalassemia.
Subscribe To Our Newsletter
Filter out the noise and nurture your inbox with health and wellness advice that's inclusive and rooted in medical expertise.
Medtalks is India's fastest growing Healthcare Learning and Patient Education Platform designed and developed to help doctors and other medical professionals to cater educational and training needs and to discover, discuss and learn the latest and best practices across 100+ medical specialties. Also find India Healthcare Latest Health News & Updates on the India Healthcare at Medtalks
Please update your details